Deoxyelephantopin impedes mammary adenocarcinoma cell motility by inhibiting calpain-mediated adhesion dynamics and inducing reactive oxygen species and aggresome formation

Free Radical Biology and Medicine

Volumn 52, Issue 8, 2012, Pages 1423-1436

  Lee, Wai Leng ^a,b,c   Shyur, Lie Fen ^a,b,c  

^a Taiwan Intl Grad Prog Computational Linguistics and Chinese Language Processing (TIGP CLCLP)   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Calpain; Cancer cell motility; Deoxyelephantopin; Focal adhesion; Free radicals; Mammary adenocarcinoma; Paclitaxel; Reactive oxygen species; Sesquiterpene lactone

Indexed keywords

ANTINEOPLASTIC AGENT; CALPAIN; DEOXYELEPHANTOPIN; PACLITAXEL; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

AGGRESOME; ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER INVASION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBONYLATION;

ACTINS; ADENOCARCINOMA; ANIMALS; CALPAIN; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LACTONES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; SESQUITERPENES;

MUS;

EID: 84862791988     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.01.020     Document Type: Article

References (49)

1. American Cancer Society Breast Cancer Facts & Figures. Am. Cancer Soc., Atlanta; 2007-2008.
2. Mariani, G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann. Oncol. 16:ii191-ii194; 2005.
3. Wang, T. H.; Wang, H. S.; Soong, Y. K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88:2619-2628; 2000.
4. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of taxol resistance related to microtubules. Oncogene 22:7280-7295; 2003.
5. Sarkar, F. H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 66:3347-3350; 2006.
6. Lee, K. H.; Cowherd, C. M.; Wolo, M. T. Antitumor agents. XV. Deoxyelephantopin, an antitumor principle from Elephantopus carolinianus Willd. J. Pharm. Sci. 64: 1572-1573; 1975.
7. Xu, G.; Liang, Q.; Gong, Z.; Yu, W.; He, S.; Xi, L. Antitumor activities of the four sesquiterpene lactones from Elephantopus scaber L. Exp. Oncol. 28:106-109; 2006.
8. Huang, C. C.; Lo, C. P.; Chiu, C. Y.; Shyur, L. F. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice. Br. J. Pharmacol. 159:856-871; 2010.
9. Lee, W. L.; Wen, T. N.; Shiau, J. Y.; Shyur, L. F. Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells. J. Proteome Res. 9:237-253; 2010.
10. Franco, S. J.; Huttenlocher, A. Regulating cell migration: calpains make the cut. J. Cell Sci. 118:3829-3838; 2005.
11. Sato, K.; Kawashima, S. Calpain function in the modulation of signal transduction molecules. Biol. Chem. 382:743-751; 2001.
12. Franco, S.; Perrin, B.; Huttenlocher, A. Isoform specific function of calpain 2 in regulating membrane protrusion. Exp. Cell Res. 299:179-187; 2004.
13. Rios-Doria, J.; Day, K. C.; Kuefer, R.; Rashid, M. G.; Chinnaiyan, A. M.; Rubin, M. A.; Day, M. L. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J. Biol. Chem. 278:1372-1379; 2003.
14. Libertini, S. J.; Robinson, B. S.; Dhillon, N. K.; Glick, D.; George, M.; Dandekar, S.; Gregg, J. P.; Sawai, E.; Mudryj, M. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res. 65:10700-10708; 2005.
15. Roumes, H.; Leloup, L.; Dargelos, E.; Brustis, J. J.; Daury, L.; Cottin, P. Calpains: markers of tumor aggressiveness? Exp. Cell Res. 316:1587-1599; 2010.
16. Hall, A.; Nobes, C. D. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton.Philos.Trans. R. Soc. Lond.B355:965-970; 2000.
17. Wójcik, C.; DeMartino, G. N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35:579-589; 2003.
18. Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade™ (Bortezomib). Cancer Invest. 22:304-311; 2004.
19. But, P. P. H.; Hon, P. M.; Cao, H.; Chan, T. D.; Wu, B. M.; Mak, T. C.; Che, C. T. Sesquiterpene lactones from Elephantopus scaber. Phytochemistry 44:113-116; 1997.
20. Matteis, M. A. D.; Morrow, J. S. Spectrin tethers and mesh in the biosynthetic pathway. J. Cell Sci. 113:2331-2343; 2000.
21. Carragher, N. O. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr. Pharm. Des. 12:615-638; 2006.
22. Shuster, C. B.; Herman, I. M. Indirect association of ezrin with F-actin: isoform specificity and calcium sensitivity. J. Cell Biol. 128:837-848; 1995.
23. Cooray, P.; Yuan, Y.; Schoenwaelder, S. M.; Mitchell, C. A.; Salem, H. H.; Jackson, S. P. Focal adhesion kinase (pp 125FAK) cleavage and regulation by calpain. Biochem. J. 318:41-47; 1996.
24. Xu, Y.; Bismar, T. A.; Su, J.; Xu, B.; Kristiansen, G.; Varga, Z.; Teng, L.; Ingber, D. E.; Mammoto, A.; Kumar, R.; Alaoui-Jamali, M. A. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J. Exp. Med. 207:2421-2437; 2010.
25. Mitra, S. K.; Hanson, D. A.; Schlaepfer, D. D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6:56-68; 2005.
26. Jockusch, B. M.; Rüdiger, M. Crosstalk between cell adhesion molecules: vinculin as a paradigm for regulation by conformation. Trends Cell Biol. 6:311-315; 1996.
27. Perrin, B. J.; Huttenlocher, A. Calpain. Int. J. Biochem. Cell Biol. 34:722-725; 2002.
28. Potter, D. A.; Tirnauer, J. S.; Janssen, R.; Croall, D. E.; Hughes, C. N.; Fiacco, K. A.; Mier, J. W.; Maki, M.; Herman, I. M. Calpain regulates actin remodeling during cell spreading. J. Cell Biol. 141:647-662; 1998.
29. Fais, S. Moulding the shape of a metastatic cell. Leuk. Res. 34:843-847; 2010.
30. Segall, J. E.; Tyerech, S.; Boselli, L.; Masseling, S.; Helft, J.; Chan, A.; Jonest, J.; Condeelis, J. EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism. Clin. Exp. Metastasis 14: 61-72; 1996.
31. Wang, Y. N.; Wang, H.; Yamaguchi, H.; Lee, H. J.; Lee, H. H.; Hung, M. C. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem. Biophys. Res. Commun. 399:498-504; 2010.
32. Fribley, A.; Wang, C. Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol. Ther. 5:745-748; 2006.
33. Wong, C. H.; Iskandar, K. B.; Yadav, S. K.; Hirpara, J. L.; Loh, T.; Pervaiz, S. Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation. PLoS One 5:e9996; 2010.
34. Baillie, T. A.; Slatter, J. G. Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo. Acc. Chem. Res. 24:264-270; 1991.
35. Grune, T.; Jung, T.; Merker, K.; Davies, K. J. A. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes'during oxidative stress, aging, and disease. Int. J. Biochem. Cell Biol. 36:2519-2530; 2004.
36. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Gagliano, N.; Simplicio, P. D.; Colombo, R.; Milzani, A. Methionine oxidation as a major cause of the functional impairment of oxidized actin. Free Radic. Biol. Med. 32:927-937; 2002.
37. Mamoune, A.; Luo, J. H.; Lauffenburger, D. A.; Wells, A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res. 63:4632-4640; 2003.
38. Glading, A.; Lauffenburger, D. A.; Wells, A. Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol. 12:46-54; 2002.
39. Chan, K. T.; Bennin, D. A.; Huttenlocher, A. Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). J. Biol. Chem. 285: 11418-11426; 2010.
40. Barret, C.; Roy, C.; Montcourrier, P.; Mangeat, P.; Niggli, V. Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP2) binding site in the NH2-terminal domain of ezrin correlates with its altered cellular distribution. J. Cell Biol. 151: 1067-1079; 2000.
41. Sadowski, L.; Pilecka, I.; Miaczynska, M. Signaling from endosomes: location makes a difference. Exp. Cell Res. 315:1601-1609; 2009.
42. Palamidessi, A.; Frittoli, E.; Garré, M.; Faretta, M.; Mione, M.; Testa, I.; Diaspro, A.; Lanzetti, L.; Scita, G.; Fiore, P. P. D. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 134:135-147; 2008.
43. García-Mata, R.; Gao, Y. S.; Sztul, E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 3:388-396; 2002.
44. Ogburn, K. D.; Figueiredo-Pereira, M. E. Cytoskeleton/endoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates. J. Biol. Chem. 281:23274-23284; 2006.
45. Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A. K.; Simms-Waldrip, T.; Fu, C.; Sakamoto, K. M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6- dependent protein degradation. Cancer Res. 68:2557-2560; 2008.
46. England, K.; O'Driscoll, C.; Cotter, T. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ. 11: 252-260; 2004.
47. Vasiliev, J. M.; Gelfand, I. M.; Domnina, L. V.; Ivanova, O. Y.; Komm, S. G.; Olshevskaja, L. V. Effect of colcemid on the locomotory behaviour of fibroblasts. J. Embryol. Exp. Morphol. 24:625-640; 1970.
48. Lu, Q.; Longo, F. M.; Zhou, H.; Massa, S. M.; Chen, Y. H. Signaling through Rho GTPase pathway as viable drug target. Curr. Med. Chem. 16:1355-1365; 2009.
49. Fang, J.; Seki, T.; Maeda, H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61:290-302; 2009.